Lord Abbett & CO. LLC Acquires 188,685 Shares of Evolus, Inc. (NASDAQ:EOLS)

Lord Abbett & CO. LLC boosted its holdings in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 23.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 995,449 shares of the company's stock after buying an additional 188,685 shares during the period. Lord Abbett & CO. LLC owned approximately 1.57% of Evolus worth $16,126,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. Quest Partners LLC bought a new position in Evolus during the second quarter worth about $43,000. Quarry LP bought a new position in Evolus during the 2nd quarter worth approximately $54,000. Profund Advisors LLC acquired a new position in Evolus during the second quarter valued at approximately $130,000. Point72 Asset Management L.P. acquired a new position in Evolus during the third quarter valued at approximately $132,000. Finally, Arizona State Retirement System raised its holdings in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock worth $158,000 after purchasing an additional 1,253 shares during the period. Institutional investors and hedge funds own 90.69% of the company's stock.

Evolus Price Performance

EOLS remained flat at $11.51 during trading on Monday. 491,414 shares of the company traded hands, compared to its average volume of 587,874. The stock has a market capitalization of $728.82 million, a P/E ratio of -12.65 and a beta of 1.27. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. Evolus, Inc. has a 1-year low of $9.65 and a 1-year high of $17.82. The stock has a 50 day moving average of $14.38 and a 200-day moving average of $13.84.

Analysts Set New Price Targets

EOLS has been the subject of several research analyst reports. Barclays boosted their price target on shares of Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Friday, September 13th. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Evolus in a report on Monday, September 16th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $22.00 price objective on shares of Evolus in a report on Friday, September 13th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.